IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科
学科主题临床医学
Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut)
Zhang, Xinpei1,2; Shi, Jinlong3; Zhang, Jilei1,2; Yang, Xinrui1,2; Zhang, Gaoqi1,2; Yang, Siyuan1,2; Wang, Jing1,2; Ke, Xiaoyan1,2; Fu, Lin1,2
通讯作者Fu, Lin(1,2)
关键词acute myeloid leukemia molecular mutations prognosis next-generation sequencing
刊名CANCER MANAGEMENT AND RESEARCH
2018
DOI10.2147/CMAR.S157632
10页:2457-2466
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]WORLD-HEALTH-ORGANIZATION ; PROGNOSTIC IMPLICATIONS ; TANDEM DUPLICATION ; IDH2 MUTATIONS ; DIFFERENTIATION ; CLASSIFICATION ; ENASIDENIB ; NEOPLASMS ; REVISION ; THERAPY
英文摘要

Purpose: The incidence of DNMT3A mutations in acute myeloid leukemia (AML) is quite high and often confers a poorer prognosis. Another common gene involved in AML is IDH1/2. However, the influence of IDH1/2 mutations on outcomes in DNMT3A-mutated patients remains unknown. This study aims to determine the effect of IDH1/2(mut) on the prognosis in patients with DNMT3A-mutated AML.

Patients and methods: We screened patients from The Cancer Genome Atlas database and selected 51 patients with AML and the DNMT3A mutation, among which 16 patients (31.4%) had both DNMT3A and IDH1/2(mut).

Results: Among our sample, 11 cases had the IDH1 mutation (21.7%), and 5 cases had the IDH2 mutation (9.8%). Patients in the DNMT3A(mut)IDH1/2(wild) group showed a greater number of NPM1 mutation (P=0.022), and higher event-free survival (EFS) and overall survival (OS) after hematopoietic stem cell transplantation (HSCT) (P=0.010 and P=0.007, respectively). Patients in the DNMT3A(mut)IDH1/2(mut) group showed no increase in EFS or OS after HSCT or chemotherapy. Other factors, like white blood cells, bone marrow blasts, peripheral blood blasts, and mutated recurrent gene numbers had no significant influence on EFS and OS.

Conclusion: The IDH1/2 gene had little influence on the prognosis of patients with the DNMT3A mutation. For patients in the DNMT3A(mut)IDH1/2(wild) group, HSCT had a more favorable therapeutic effect. For patients with DNMT3A and IDH1/2(mut), chemotherapy and HSCT appeared to have similar efficacy.

语种英语
WOS记录号WOS:000440787700002
通讯作者邮箱fulin022@126.com
第一作者单位Peking Univ, Hosp 3, Dept Hematol, 49 North Garden Rd, Beijing 100191, Peoples R China ; Peking Univ, Hosp 3, Lymphoma Res Ctr, 49 North Garden Rd, Beijing 100191, Peoples R China
通讯作者单位Peking Univ, Hosp 3, Dept Hematol, 49 North Garden Rd, Beijing 100191, Peoples R China ; Peking Univ, Hosp 3, Lymphoma Res Ctr, 49 North Garden Rd, Beijing 100191, Peoples R China
ISSN1179-1322
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142622
专题北京大学第三临床医学院_血液内科
北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Hosp 3, Dept Hematol, 49 North Garden Rd, Beijing 100191, Peoples R China;
2.Peking Univ, Hosp 3, Lymphoma Res Ctr, 49 North Garden Rd, Beijing 100191, Peoples R China;
3.Chinese Peoples Liberat Army Gen Hosp, Dept Biomed Engn, Beijing 100853, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Xinpei,Shi, Jinlong,Zhang, Jilei,et al. Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut)[J]. CANCER MANAGEMENT AND RESEARCH,2018,10:2457-2466.
APA Zhang, Xinpei.,Shi, Jinlong.,Zhang, Jilei.,Yang, Xinrui.,Zhang, Gaoqi.,...&Fu, Lin.(2018).Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut).CANCER MANAGEMENT AND RESEARCH,10,2457-2466.
MLA Zhang, Xinpei,et al."Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut)".CANCER MANAGEMENT AND RESEARCH 10(2018):2457-2466.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Xinpei]的文章
[Shi, Jinlong]的文章
[Zhang, Jilei]的文章
百度学术
百度学术中相似的文章
[Zhang, Xinpei]的文章
[Shi, Jinlong]的文章
[Zhang, Jilei]的文章
必应学术
必应学术中相似的文章
[Zhang, Xinpei]的文章
[Shi, Jinlong]的文章
[Zhang, Jilei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。